Dr. Marc Klapholz is the principal investigator of a Phase II clinical trial. Patients with acute myocardial infarction are treated with autologous bone marrow derived CD34+/CXCR4+ cells. The trial is supported by Amorcyte, which is a subsidiary of Neostem. The patients are infused with the CD34+CXCR4+ cells at 5-11 days after infarction.

Dr. Klapholz is the Chairman, Department of Medicine at New Jersey Medical School and Director, Division of Cardiology.